Affimed Reports Second Quarter 2024 Financial Results & Business Update

GlobeNewswire09-05

AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable patients: 1 complete response (CR), 3 partial ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465546366?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Z3uhFOknuNPk4kuWaxxLPw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/dbbba12c81b876466ec0f745c48ed883","is_english":true,"pubTime":"2024-09-05 18:30","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2465546366","market":"us","top_or_hot":-1,"title":"Affimed Reports Second Quarter 2024 Financial Results & Business Update","media":"GlobeNewswire","content":"<div>\n<p>AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable patients: 1 complete response (CR), 3 partial ...</p>\n\n<a href=\"https://finance.yahoo.com/news/affimed-reports-second-quarter-2024-103000750.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Affimed Reports Second Quarter 2024 Financial Results & Business Update</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAffimed Reports Second Quarter 2024 Financial Results & Business Update\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-05 18:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/affimed-reports-second-quarter-2024-103000750.html><strong>GlobeNewswire</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable patients: 1 complete response (CR), 3 partial ...</p>\n\n<a href=\"https://finance.yahoo.com/news/affimed-reports-second-quarter-2024-103000750.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4210","symbol_name":"白银","start_time":0,"source_url":"https://finance.yahoo.com/news/affimed-reports-second-quarter-2024-103000750.html","article_id":"2465546366","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Z3uhFOknuNPk4kuWaxxLPw--~B/aD00MDA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/dbbba12c81b876466ec0f745c48ed883"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465546366","pubTimestamp":1725532200,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant  non-small cell lung cancer  cohort; in 17 response-evaluable patients: 1 complete response , 3 partial responses  and 8 stable diseases  were reported. Objective response rate  is 23.5%  and disease control rate  is 70.6% . Median follow-up of > 7 months, 8 of 17 patients continue on treatment.The EGFR wild type  cohort of treatment refractory NSCLC patients has treated 40 patients;ORR and safety data is expected in Q4 2024. Cash runway into H2 2025: As of June 30, 2024, cash, cash equivalents and investments were 34.4 million. Based on operating and financial plans cash-runway projected into H2 2025.MANNHEIM, Germany, Sept. 05, 2024  -- Affimed N.V.  , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the quarter ended June 30, 2024.24 heavily pretreated","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4210":"白银","BK4570":"地缘局势概念股","CR":"crane","BK4139":"生物科技","HL":"赫克拉矿业","AFMD":"Affimed NV","BK4161":"工业机械"},"translate_title":"Affimed报告2024年第二季度财务业绩和业务更新","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CR":1,"HL":1,"AFMD":0.9},"content_text":"AFM24 combination with atezolizumab: 24 patients treated in the EGFR mutant (EGFRmut) non-small cell lung cancer (NSCLC) cohort; in 17 response-evaluable patients: 1 complete response (CR), 3 partial responses (PRs) and 8 stable diseases (SDs) were reported. Objective response rate (ORR) is 23.5% (4/17) and disease control rate (DCR) is 70.6% (12/17). Median follow-up of > 7 months, 8 of 17 patients continue on treatment.\nThe EGFR wild type (EGFRwt) cohort of treatment refractory NSCLC patients has treated 40 patients; ORR and safety data is expected in Q4 2024 \nAcimtamig (AFM13) combination with AlloNK® (AB-101): Enrollment for relapsed/refractory (r/r) Hodgkin Lymphoma (HL) patients in cohorts 1 and 2 is completed (n=12); cohort 3 and cohort 4 recruitment on track (10/12 patients). In cohort 1 and 2, an ORR of 83.3% (10/12) and a complete response rate (CRR) of 50% (6/12) were observed.\nAFM28 monotherapy phase 1 dose-escalation study: Of the 6 patients with relapsed/refractory Acute Myeloid Leukemia (r/r AML) treated at dose level 6 (300 mg weekly), 3 patients showed either a CR or complete response with incomplete hematological recovery (CRi). Based on the encouraging activity an additional 6 patients will be recruited at 300 mg.\nCash runway into H2 2025: As of June 30, 2024, cash, cash equivalents and investments were €34.4 million. Based on operating and financial plans cash-runway projected into H2 2025.\n\nMANNHEIM, Germany, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results and provided an update on clinical and corporate progress for the quarter ended June 30, 2024.\n“We continue to generate compelling data across our clinical programs,\" said Dr. Andreas Harstrick, Chief Medical Officer of Affimed. \"In solid tumors, our combination study is making significant progress, and we are excited to see objective responses and meaningful tumor control, even in patients with EGFR mutant lung cancer — a disease often resistant to immunomodulation. It's particularly encouraging that these outcomes are achieved without chemotherapy, which is important given the intolerance many pretreated patients have for such treatments. Our programs in hematologic malignancies are also advancing well. Recent updates from the 12 patients of the LuminICE-203 study reveal remarkable efficacy, in an advanced Hodgkin lymphoma population that had exhausted all approved treatment options. Additionally, AFM28 continues to show promise as a monotherapy in AML. The data shared today underscore our strategy of leveraging the innate immune system in our fight against cancer and reinforce our commitment to advancing these clinical programs.\"\nPipeline Highlights:\nAFM24 (EGFR / CD16A)In the AFM24-102 trial (combination with atezolizumab):\n\n24 heavily pretreated EGFRmut NSCLC patients are in the trial; in 17 patients that are response evaluable per protocol, 1 CR, 3 PRs and 8 SDs were observed. All responses have been confirmed by follow-up scan. ORR is 23.5% (4/17) and DCR is 70.6% (12/17). Median follow-up is > 7 months and 8 out of the 17 patients continue on treatment. All 4 responders remained on treatment for at least 7 months. Final PFS data from the EGFRmut cohort is expected at a scientific conference in H1 2025.\nAll patients were pretreated with TKIs (~60% with third generation TKIs) and the majority (76%) had also received platinum-based chemotherapy.\nThe EGFRwt NSCLC cohort of patients who failed chemotherapy and PD-1/PD-L1 has continued enrollment, with 40 patients on trial. ORR and safety for this cohort is expected in Q4 2024. \nIn May, the Company received FDA Fast Track designation for the combination treatment of AFM24 with atezolizumab for EGFRwt NSCLC patients.\n\nAcimtamig (AFM13; CD30 / CD16A)High efficacy observed in the first 12 patients with advanced HL in cohorts 1 and 2 of the Phase 2 LuminICE-203 study showing an ORR of 83.3 % and CRR of 50%. \n\nIn the multi-center, multi-cohort, open-label Phase 2 LuminICE-203 trial, patients with advanced, treatment refractory Hodgkin Lymphoma receive combination of CD30-targeting innate cell engager acimtamig (AFM13) with AlloNK.\nAll HL patients were heavily pretreated with a median of 4 lines of prior therapy, having exhausted all standard of care treatment options, including combination chemotherapy, brentuximab vedotin and checkpoint inhibitors; 50% of patients had also failed prior autologous or allogeneic stem cell transplantation (SCT).\nEnrollment in cohorts 1 and 2 (acimtamig doses of 200 mg or 300 mg; AlloNK 2x109 per week for 3 weeks) is completed: In the 12 patients, 6 CRs and 4 PRs were observed.\nEnrollment in cohorts 3 and 4 (acimtamig 200 mg or 300 mg; 4x109 in week one and 2x109 AlloNK in weeks 2 and 3) has progressed well with 10/12 patients on study.\nTreatment related adverse events were consistent with previous experience and side effects related to acimtamig and AlloNK were well manageable with standard of care treatment.\nData from the study is expected to be presented at a scientific conference in Q4 2024.\n\nAFM28 (CD123 / CD16A)In the sixth cohort (300 mg) of the multi-center Phase 1 open-label, dose-escalation study (AFM28-101), of AFM28 monotherapy in CD123-positive r/r AML, 3 out of 6 patients (50%) showed a CR or CRi.\n\nOf 6 patients treated at dose level 6 at 300 mg, 1 patient showed a CR, 2 patients a CRi for a composite complete response rate (CRcR, defined as CR+CRi) of 50% (3/6) and 2 patients achieved SD.\nOf 6 patients treated at dose level 5 at 250 mg, 1 patient showed a CR, lasting 6 months, a CRR of 17% (1/6) ; the other 5 patients achieved SD as best response.\nNo dose-limiting toxicities were reported in dose levels 5 and 6.\nAn additional 6 patients will be enrolled at 300 mg of AFM28.\nData from the study is expected to be presented at a scientific conference in Q4 2024.\n\nUpcoming Milestones:\n\nLuminICE-203: Efficacy update of cohorts 1-4 expected to be presented at a future scientific conference in Q4 2024.\nAFM24-102: ORR and safety data from the EGFRwt cohort in Q4 2024.\nAFM28-101: Data from the study is expected to be presented at a scientific conference in Q4 2024.\nAMF24-102: Mature PFS data from EGFRmut and EGFRwt cohorts expected to be presented at a future conference in H1 2025.\n\nSecond Quarter 2024 Financial HighlightsAffimed’s consolidated financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) as issued by the International Accounting Standard Board (IASB). The consolidated financial statements are presented in Euros (€), the Company’s functional and presentation currency.\nAs of June 30, 2024, cash, cash equivalents and short-term investments totaled €34.4 million. Based on current operating and budget assumptions, the Company expects that cash, cash equivalents and investments, together with anticipated proceeds from its ATM program and the sale of AbCheck, will finance its operations into the second half of 2025.\nNet cash used in operating activities for the quarter ended June 30, 2024 was €16.5 million compared to €33.2 million for the quarter ended June 30, 2023. The decline was mainly due to lower research and development expenditure and personnel expenses due to the reduction in head count.   \nTotal revenue for the quarter ended June 30, 2024, was €0.2 million compared with €1.4 million for the quarter ended June 30, 2023. Revenue in 2024 only related to a platform license provided to Genentech and 2023 predominantly related to the Roivant research collaborations for which all work has been completed. \nResearch and development expenses for the quarter ended June 30, 2024, were €11.7 million compared to €25.3 million in 2023. The decrease was primarily a result of lower expenses associated with the development of acimtamig and AFM24, due to a decrease in procurement of clinical trial material, clinical trial costs and manufacturing costs, decrease in head count due to the corporate restructuring.\nGeneral and administrative expenses for the quarter ended June 30, 2024, were €4.0 million compared to €6.3 million for the quarter ended June 30, 2023. The decrease was due to declines in headcount, in legal and consulting expenses, insurance expenses and share-based payment expenses. \nNet loss for the quarter ended June 30, 2024, was €15.5 million, or €1.01 loss per common share compared with a net loss of €29.4 million, or €1.97 loss per common share, for the quarter ended June 30, 2023. \nThe weighted number of common shares outstanding for the quarter ended June 30, 2024, was 15,300,912 shares. \nAdditional information regarding these results will be included in the notes to the consolidated financial statements as of June 30, 2024, included in Affimed’s filings with the U.S. Securities and Exchange Commission (SEC). \nNote on International Financial Reporting Standards (IFRS) Affimed prepares and reports consolidated financial statements and financial information in accordance with IFRS as issued by the IASB. None of the financial statements were prepared in accordance with U.S. Generally Accepted Accounting Principles. Affimed maintains its books and records in Euro. \nConference Call and Webcast InformationAffimed will host a conference call and webcast on September 5, 2024, at 8:30 a.m. EDT / 14:30 CET to discuss second quarter 2024 financial results and corporate developments.\nThe conference call will be available via phone and webcast. The live audio webcast of the call will be available in the “Webcasts” section on the “Investors” page of the Affimed website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. To access the call by phone, please use link: https://register.vevent.com/register/BI53034c7725d043b0854377307e1cd8a3, and you will be provided with dial-in details and a pin number.\nNote: To avoid delays, we encourage participants to dial into the conference call 15 minutes ahead of the scheduled start time. A replay of the webcast will be accessible at the same link for 30 days following the call.\nAbout Affimed N.V.Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells.  A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.\nForward-Looking StatementThis press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements appear in a number of places throughout this release and include statements regarding the Company’s intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the potential of acimtamig (AFM13), AFM24, AFM28 and the Company’s other product candidates, the value of its ROCK® platform, its ongoing and planned preclinical development and clinical trials, its collaborations and development of its products in combination with other therapies, the timing of and its ability to make regulatory filings and obtain and maintain regulatory approvals for its product candidates, its intellectual property position, its collaboration activities, its ability to develop commercial functions, clinical trial data, its results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies, the industry in which it operates, the macroeconomic trends that may affect the industry or the Company, such as the instability in the banking sector experienced in the first quarter of 2023, impacts of the COVID-19 pandemic, the benefits to Affimed of orphan drug designation, the impact on its business by political events, war, terrorism, business interruptions and other geopolitical events and uncertainties, such as the Russia-Ukraine conflict, the fact that the current clinical data of (AFM13) acimtamig in combination with NK cell therapy is based on AFM13 (acimtamig) precomplexed with fresh allogeneic cord blood-derived NK cells from The University of Texas MD Anderson Cancer Center, as opposed to Artiva’s AlloNK® (AB-101) and other uncertainties and factors described under the heading “Risk Factors” in Affimed’s filings with the SEC. Given these risks, uncertainties, and other factors, you should not place undue reliance on these forward-looking statements, and the Company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.        Investor Relations Contact Alexander FudukidisDirector, Investor RelationsE-Mail: a.fudukidis@affimed.com\nTel.: +1 (917) 436-8102\n\n\n\nAffimed N.V.\n \n \n \n \n \n \n\n\nUnaudited consolidated interim statements of comprehensive loss\n \n\n\n(in € thousand)\n \n \n \n \n \n \n\n\n \n \n \n \n \n\n\n \n \nFor the three months ended June 30\n \nFor the six months ended June 30\n\n\n \n \n2024\n \n2023\n \n \n2024\n \n2023\n \n\n\nRevenue\n \n154\n \n1,390\n \n \n309\n \n5,900\n \n\n\n \n \n \n \n \n \n \n\n\nOther income - net\n \n56\n \n717\n \n \n233\n \n1,127\n \n\n\nResearch and development expenses\n \n(11,727\n)\n(25,273\n)\n \n(27,118\n)\n(54,804\n)\n\n\nGeneral and administrative expenses\n \n(4,036\n)\n(6,276\n)\n \n(8,512\n)\n(13,126\n)\n\n\n \n \n \n \n \n \n \n\n\nOperating loss\n \n(15,553\n)\n(29,442\n)\n \n(35,088\n)\n(60,903\n)\n\n\n \n \n \n \n \n \n \n\n\nFinance income / (costs) - net\n \n105\n \n47\n \n \n465\n \n(472\n)\n\n\n \n \n \n \n \n \n \n\n\nLoss before tax\n \n(15,448\n)\n(29,395\n)\n \n(34,623\n)\n(61,375\n)\n\n\n \n \n \n \n \n \n \n\n\nIncome taxes\n \n(3\n)\n0\n \n \n(3\n)\n(3\n)\n\n\n \n \n \n \n \n \n \n\n\nLoss for the period\n \n(15,451\n)\n(29,395\n)\n \n(34,626\n)\n(61,378\n)\n\n\n \n \n \n \n \n \n \n\n\n \n \n \n \n \n \n \n\n\nTotal comprehensive loss\n \n(15,451\n)\n(29,395\n)\n \n(34,626\n)\n(61,378\n)\n\n\n \n \n \n \n \n \n \n\n\nBasic and diluted loss per share in € per share (undiluted = diluted)\n \n(1.01\n)\n(1.97\n)\n \n(2.28\n)\n(4.11\n)\n\n\nWeighted number of common shares outstanding\n \n15,300,912\n \n14,933,934\n \n \n15,212,555\n \n14,933,934\n \n\n\n \n \n \n \n \n \n \n\n\n\n\n\n\nAffimed N.V.\n \n \n \n \n\n\nConsolidated interim statements of financial position\n \n \n \n \n\n\n(in € thousand)\n \n \n \n \n\n\n \n \nJune 30, 2024 (unaudited)\n \nDecember 31, 2023\n\n\nASSETS\n \n \n \n \n\n\nNon-current assets\n \n \n \n \n\n\nIntangible assets\n \n18\n \n \n25\n \n\n\nLeasehold improvements and equipment\n \n2,331\n \n \n4,905\n \n\n\nRight-of-use assets\n \n5,638\n \n \n8,039\n \n\n\n \n \n7,987\n \n \n12,969\n \n\n\nCurrent assets\n \n \n \n \n\n\nCash and cash equivalents\n \n10,764\n \n \n38,529\n \n\n\nInvestments\n \n23,683\n \n \n33,518\n \n\n\nOther financial assets\n \n878\n \n \n851\n \n\n\nTrade and other receivables\n \n5,717\n \n \n5,327\n \n\n\nInventories\n \n0\n \n \n463\n \n\n\nOther assets and prepaid expenses\n4,145\n \n \n5,500\n \n\n\n \n \n45,187\n \n \n84,188\n \n\n\n \n \n \n \n \n\n\nTOTAL ASSETS\n \n53,174\n \n \n97,157\n \n\n\n \n \n \n \n \n\n\nEQUITY AND LIABILITIES\n \n \n \n \n\n\nEquity\n \n \n \n \n\n\nIssued capital\n \n1,568\n \n \n1,500\n \n\n\nCapital reserves\n \n599,131\n \n \n593,666\n \n\n\nFair value reserves\n \n(1,231\n)\n \n(1,231\n)\n\n\nAccumulated deficit\n \n(570,754\n)\n \n(536,128\n)\n\n\nTotal equity \n \n28,714\n \n \n57,807\n \n\n\n \n \n \n \n \n\n\nNon current liabilities\n \n \n \n \n\n\nBorrowings\n3,603\n \n \n6,319\n \n\n\nContract liabilities\n \n155\n \n \n464\n \n\n\nLease liabilities\n \n4,030\n \n \n6,660\n \n\n\nTotal non-current liabilities\n \n7,788\n \n \n13,443\n \n\n\n \n \n \n \n \n\n\nCurrent liabilities\n \n \n \n \n\n\nTrade and other payables\n \n9,171\n \n \n18,916\n \n\n\nBorrowings\n5,833\n \n \n5,833\n \n\n\nLease liabilities\n \n1,049\n \n \n539\n \n\n\nContract liabilities\n619\n \n \n619\n \n\n\nTotal current liabilities\n \n16,672\n \n \n25,907\n \n\n\n \n \n \n \n \n\n\nTOTAL EQUITY AND LIABILITIES\n \n53,174\n \n \n97,157\n \n\n\n \n \n \n \n \n\n\n\n\n\n\nAffimed N.V.\n \n \n \n \n\n\nUnaudited consolidated interim statements of cash flows\n \n \n \n \n\n\n(in € thousand)\n \n\n\n \n \nFor the six months ended June 30\n\n\n \n \n2024\n \n2023\n\n\nCash flow from operating activities\n \n \n \n \n\n\nLoss for the period\n \n(34,626\n)\n \n(61,378\n)\n\n\nAdjustments for the period:\n \n \n \n \n\n\n- Income taxes\n \n3\n \n \n3\n \n\n\n- Depreciation and amortization\n \n2,520\n \n \n577\n \n\n\n- Net gain on disposal of leasehold improvements and equipment\n \n(24\n)\n \n0\n \n\n\n- Loss from write-down of inventories\n \n456\n \n \n0\n \n\n\n- Share-based payments\n \n1,472\n \n \n7,389\n \n\n\n- Finance income / (costs) - net\n \n(465\n)\n \n472\n \n\n\n \n \n(30,664\n)\n \n(52,937\n)\n\n\nChange in trade and other receivables\n \n(391\n)\n \n543\n \n\n\nChange in inventories\n \n7\n \n \n(66\n)\n\n\nChange in other assets and prepaid expenses\n \n1,525\n \n \n(5,473\n)\n\n\nChange in trade, other payables, provisions and contract liabilities\n \n(10,308\n)\n \n(8,867\n)\n\n\n \n \n(39,831\n)\n \n(66,800\n)\n\n\nInterest received\n \n155\n \n \n924\n \n\n\nPaid interest\n \n(648\n)\n \n(695\n)\n\n\nPaid income tax\n \n(3\n)\n \n(3\n)\n\n\nNet cash used in operating activities\n \n(40,327\n)\n \n(66,574\n)\n\n\n \n \n \n \n \n\n\nCash flow from investing activities\n \n \n \n \n\n\nPurchase of leasehold improvements and equipment, including upfront payments for right-of-use assets\n \n(20\n)\n \n(11\n)\n\n\nCash received from the sale of financial assets\n \n10,857\n \n \n0\n \n\n\nCash received from the sale of leasehold improvements and equipment\n \n768\n \n \n0\n \n\n\nNet cash generated / (used) for investing activities\n \n11,605\n \n \n(11\n)\n\n\n \n \n \n \n \n\n\nCash flow from financing activities\n \n \n \n \n\n\nProceeds from issue of common shares, including exercise of share-based payment awards\n \n4,256\n \n \n0\n \n\n\nTransaction costs related to issue of common shares\n \n(112\n)\n \n0\n \n\n\nRepayment of lease liabilities\n \n(413\n)\n \n(249\n)\n\n\nRepayment of borrowings\n \n(2,917\n)\n \n(2,965\n)\n\n\nNet cash generated / (used) for financing activities\n \n814\n \n \n(3,214\n)\n\n\n \n \n \n \n \n\n\nExchange-rate related changes of cash and cash equivalents\n \n143\n \n \n(431\n)\n\n\nNet changes to cash and cash equivalents\n \n(27,908\n)\n \n(69,799\n)\n\n\nCash and cash equivalents at the beginning of the period\n \n38,529\n \n \n190,286\n \n\n\nCash and cash equivalents at the end of the period\n \n10,764\n \n \n120,056\n \n\n\n \n \n \n \n \n\n\n\n\n\n\nAffimed N.V.\n \n \n \n \n \n \n \n \n \n \n\n\nUnaudited consolidated interim statements of changes in equity for the year\n \n \n \n \n\n\n(in € thousand)\n \n \n \n \n \n \n \n \n \n \n\n\n \n \nIssued capital\n \nCapital reserves\n \nFair Value reserves\n \nAccumulated deficit\n \nTotal equity\n\n\n \n \n \n \n \n \n \n \n \n \n \n\n\nBalance as of January 1, 2023\n \n1,493\n \n582,843\n \n(1,231\n)\n \n(430,190\n)\n \n152,915\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n\n\nEquity-settled share-based payment awards\n \n \n \n7,389\n \n \n \n \n \n7,389\n \n\n\nLoss for the period\n \n \n \n \n \n \n \n(61,378\n)\n \n(61,378\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n\n\nBalance as of June 30, 2023\n \n1,493\n \n590,232\n \n(1,231\n)\n \n(491,568\n)\n \n98,926\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n\n\nBalance as of January 1, 2024\n \n1,500\n \n593,666\n \n(1,231\n)\n \n(536,128\n)\n \n57,807\n \n\n\n \n \n \n \n \n \n \n \n \n \n \n\n\nIssue of common shares\n \n68\n \n3,993\n \n \n \n \n \n4,061\n \n\n\nEquity-settled share-based payment awards\n \n \n \n1,472\n \n \n \n \n \n1,472\n \n\n\nLoss for the period\n \n \n \n \n \n \n \n(34,626\n)\n \n(34,626\n)\n\n\n \n \n \n \n \n \n \n \n \n \n \n\n\nBalance as of June 30, 2024\n \n1,568\n \n599,131\n \n(1,231\n)\n \n(570,754\n)\n \n28,714","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.27.0","shortVersion":"4.27.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465546366"}